WO2001079487A3 - Polydesoxyribonukleotide zur hemmung der icam-1-genexpression - Google Patents

Polydesoxyribonukleotide zur hemmung der icam-1-genexpression Download PDF

Info

Publication number
WO2001079487A3
WO2001079487A3 PCT/DE2001/001509 DE0101509W WO0179487A3 WO 2001079487 A3 WO2001079487 A3 WO 2001079487A3 DE 0101509 W DE0101509 W DE 0101509W WO 0179487 A3 WO0179487 A3 WO 0179487A3
Authority
WO
WIPO (PCT)
Prior art keywords
icam
polydesoxyribonucleotides
inhibiting
gene
expression
Prior art date
Application number
PCT/DE2001/001509
Other languages
English (en)
French (fr)
Other versions
WO2001079487A2 (de
Inventor
Klaus Karl Degitz
Robert Besch
Original Assignee
Klaus Karl Degitz
Robert Besch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klaus Karl Degitz, Robert Besch filed Critical Klaus Karl Degitz
Priority to AU2001273847A priority Critical patent/AU2001273847A1/en
Publication of WO2001079487A2 publication Critical patent/WO2001079487A2/de
Publication of WO2001079487A3 publication Critical patent/WO2001079487A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent

Abstract

Die vorliegende Erfindung betrifft Triplehelix-Oligonukleotide, die sich an doppelsträngige genomische ICAM-1-DNA-Sequenzen anlagern und so die Transkription hemmen. Ferner betrifft die vorliegende Erfindung die Verwendung der Polydesoxyribonukleotide als therapeutische Mittel zur Therapie oder Prophylaxe von ICAM-1 assoziierten Erkrankungen.
PCT/DE2001/001509 2000-04-18 2001-04-18 Polydesoxyribonukleotide zur hemmung der icam-1-genexpression WO2001079487A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001273847A AU2001273847A1 (en) 2000-04-18 2001-04-18 Polydesoxyribonucleotides for inhibiting the expression of the icam-1-gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10019252A DE10019252A1 (de) 2000-04-18 2000-04-18 Polydesoxyribonukleotide zur Hemmung der ICAM-1-Genexpression
DE10019252.1 2000-04-18

Publications (2)

Publication Number Publication Date
WO2001079487A2 WO2001079487A2 (de) 2001-10-25
WO2001079487A3 true WO2001079487A3 (de) 2002-06-20

Family

ID=7639214

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2001/001509 WO2001079487A2 (de) 2000-04-18 2001-04-18 Polydesoxyribonukleotide zur hemmung der icam-1-genexpression

Country Status (3)

Country Link
AU (1) AU2001273847A1 (de)
DE (1) DE10019252A1 (de)
WO (1) WO2001079487A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUB20155754A1 (it) * 2015-11-20 2017-05-20 Mastelli S R L Composizione per il trattamento di malattie imfiammatorie intestinali.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014769A1 (en) * 1992-01-31 1993-08-05 The Regents Of The University Of California Method for making universal donor cells
WO1995004749A1 (en) * 1993-08-05 1995-02-16 Isis Pharmaceuticals, Inc. Oligomers for modulating metabolic function
EP0688784A2 (de) * 1994-06-15 1995-12-27 Hoechst Aktiengesellschaft Neue 3'-Modifizierte Oligonucleotid-Derivate
WO2001029262A2 (en) * 1999-10-15 2001-04-26 Orchid Biosciences, Inc. Genotyping reagents, kits and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3056889A (en) * 1988-01-21 1989-08-11 Yale University Selective inhibition of gene expression by photoactivatable oligonucleotides
US6111094A (en) * 1990-08-14 2000-08-29 Isis Pharmaceuticals Inc. Enhanced antisense modulation of ICAM-1
US6096722A (en) * 1990-08-14 2000-08-01 Isis Pharmaceuticals Inc. Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2732544B2 (ja) * 1990-08-14 1998-03-30 アイシス・ファーマシューティカルス・インコーポレーテッド 細胞接着のオリゴヌクレオチド変調
US5580969A (en) * 1992-07-24 1996-12-03 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ICAM-I RNA
WO1994005333A1 (en) * 1992-09-02 1994-03-17 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
WO1996015780A1 (en) * 1994-11-23 1996-05-30 Isis Pharmaceuticals, Inc. Compositions and methods for preventing and treating allograft rejection
AU1564897A (en) * 1996-12-02 1998-06-29 Glenn D Hoke Antisense inhibition of human adhesion molecules
US6277967B1 (en) * 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
CN1317009A (zh) * 1998-08-03 2001-10-10 东卡罗来纳大学 低腺苷反义寡核苷酸制剂、组合物、试剂盒及处理
US6114517A (en) * 1998-12-10 2000-09-05 Isis Pharmaceuticals Inc. Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014769A1 (en) * 1992-01-31 1993-08-05 The Regents Of The University Of California Method for making universal donor cells
WO1995004749A1 (en) * 1993-08-05 1995-02-16 Isis Pharmaceuticals, Inc. Oligomers for modulating metabolic function
EP0688784A2 (de) * 1994-06-15 1995-12-27 Hoechst Aktiengesellschaft Neue 3'-Modifizierte Oligonucleotid-Derivate
WO2001029262A2 (en) * 1999-10-15 2001-04-26 Orchid Biosciences, Inc. Genotyping reagents, kits and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Abstracts for the 30th European Society for Dermatological Research Annual Meeting;Berlin, Germany; September 21-23, 2000 *
BESCH R ET AL: "Triplehelix-mediated inhibition of ICAM-1 expression in epidermal keratinocytes. An approach to the development of antigene drugs.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 115, no. 3, September 2000 (2000-09-01), pages 530, XP001041436, ISSN: 0022-202X *
LUEFTL MATTHIAS ET AL: "PUVA inhibits DNA replication, but not gene transcription at nonlethal dosages.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 111, no. 3, 1998, pages 399 - 405, XP001041434, ISSN: 0022-202X *
THUONG N T ET AL: "SEQUENCE-SPECIFIC RECOGNITION AND MODIFICATION OF DOUBLE-HELICAL DNA BY OLIGONUCLEOTIDES", ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, vol. 32, no. 5, 1 May 1993 (1993-05-01), pages 666 - 690, XP000377152, ISSN: 0570-0833 *

Also Published As

Publication number Publication date
AU2001273847A1 (en) 2001-10-30
DE10019252A1 (de) 2001-10-31
WO2001079487A2 (de) 2001-10-25

Similar Documents

Publication Publication Date Title
MXPA04000179A (es) Oligonucleotidos sinteticos de hebra doble para inhibicion especifica de expresion de gene.
HRP20130602T1 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
WO2001047944A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2004006858A3 (en) Compounds, compositions, and methods employing same
GB0223040D0 (en) Therapeutic compounds
WO2004009610A3 (en) Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
HUP0202794A2 (en) Oligonucleotides for inhibiting the expression of human eg5
IL151388A (en) Use of il-18 inhibitors
WO2001087343A3 (en) Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2003012051A8 (en) Inhibitor of dna methylation
YU57803A (sh) Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja
WO2001079487A3 (de) Polydesoxyribonukleotide zur hemmung der icam-1-genexpression
WO2003002528A3 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO2001048245A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2001040521A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2004083155A3 (en) Nucleotide lipid ester derivatives
WO2004071453A3 (en) Compositions and methods for treatment of pouchitis
WO2005107464A3 (en) Compounds and compositions as cathepsin s inhibitors
WO2001051670A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2000029622A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2004061088A3 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO2001038586A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2004053094A3 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP